Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul;9(7):e58.
doi: 10.1016/S2213-2600(21)00211-3. Epub 2021 May 12.

Inhaled budesonide for early treatment of COVID-19

Rafael San-Juan  1 , Mario Fernández-Ruiz  2 , Francisco López-Medrano  2 , José María Aguado  2
Affiliations
Comment

Inhaled budesonide for early treatment of COVID-19

Rafael San-Juan et al. Lancet Respir Med. 2021 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Comment in

Comment on

  • Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.
    Ramakrishnan S, Nicolau DV Jr, Langford B, Mahdi M, Jeffers H, Mwasuku C, Krassowska K, Fox R, Binnian I, Glover V, Bright S, Butler C, Cane JL, Halner A, Matthews PC, Donnelly LE, Simpson JL, Baker JR, Fadai NT, Peterson S, Bengtsson T, Barnes PJ, Russell REK, Bafadhel M. Ramakrishnan S, et al. Lancet Respir Med. 2021 Jul;9(7):763-772. doi: 10.1016/S2213-2600(21)00160-0. Epub 2021 Apr 9. Lancet Respir Med. 2021. PMID: 33844996 Free PMC article. Clinical Trial.

References

    1. Ramakrishnan S, Nicolau DV, Jr, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021 doi: 10.1016/S2213-2600(21)00160-0. published online April 9. - DOI - PMC - PubMed